将多巴胺转运体拮抗剂凡诺塞林重新用于治疗结直肠癌。

IF 23.5 1区医学 Q1 ONCOLOGY

Nature cancer Pub Date : 2024-02-13 DOI:10.1038/s43018-024-00723-2

Winnie Chen, Ian Maze

引用次数: 0

摘要

自我更新的癌症干细胞驱动着肿瘤的发生和发展，是治疗开发的主要目标。现在的一项研究表明，多巴胺转运体拮抗剂凡诺塞林能精确抑制结直肠癌中的这一细胞群，从而减少肿瘤的发生，增加免疫细胞的浸润。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

Repurposing the dopamine transporter antagonist vanoxerine to treat colorectal cancer

查看原文本刊更多论文

Repurposing the dopamine transporter antagonist vanoxerine to treat colorectal cancer

Self-renewing cancer stem cells drive tumor initiation and progression and represent a major target for therapeutic development. A study now shows that vanoxerine, a dopamine transporter antagonist, precisely inhibits this cell population in colorectal cancer, which leads to attenuation of tumor initiation and increased infiltration by immune cells.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Nature cancer Medicine-Oncology

CiteScore

31.10

自引率

1.80%

发文量

129

期刊介绍： Cancer is a devastating disease responsible for millions of deaths worldwide. However, many of these deaths could be prevented with improved prevention and treatment strategies. To achieve this, it is crucial to focus on accurate diagnosis, effective treatment methods, and understanding the socioeconomic factors that influence cancer rates. Nature Cancer aims to serve as a unique platform for sharing the latest advancements in cancer research across various scientific fields, encompassing life sciences, physical sciences, applied sciences, and social sciences. The journal is particularly interested in fundamental research that enhances our understanding of tumor development and progression, as well as research that translates this knowledge into clinical applications through innovative diagnostic and therapeutic approaches. Additionally, Nature Cancer welcomes clinical studies that inform cancer diagnosis, treatment, and prevention, along with contributions exploring the societal impact of cancer on a global scale. In addition to publishing original research, Nature Cancer will feature Comments, Reviews, News & Views, Features, and Correspondence that hold significant value for the diverse field of cancer research.